FENC
Fennec Pharmaceuticals Inc.NASDAQHealthcare$6.42+0.16%ClosedMarket Cap: $183.5M
As of 2026-04-06
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
5.71
P/S
4.09
EV/EBITDA
-23.01
DCF Value
$-12.51
FCF Yield
-6.8%
Div Yield
0.0%
Margins & Returns
Gross Margin
91.5%
Operating Margin
-15.1%
Net Margin
-22.7%
ROE
-236.4%
ROA
-14.5%
ROIC
-11.4%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $14.0M | $-5.2M | $-0.17 |
| FY 2025 | $45.4M | $-10.3M | $-0.36 |
| Q3 2025 | $12.5M | $-638.0K | $-0.02 |
| Q2 2025 | $9.7M | $-3.2M | $-0.12 |
Analyst Ratings
View AllHC Wainwright & Co.Buy
2025-08-21Craig-HallumBuy
2025-08-15HC Wainwright & Co.Buy
2025-05-20Craig-HallumBuy
2025-05-14Trading Activity
Insider Trades
View AllCioffi Christiana Marieofficer: Chief Strategy Officer
SellThu Apr 02
Cioffi Christiana Marieofficer: Chief Strategy Officer
SellThu Apr 02
Hackman Jeffrey S.director, officer: Chief Executive Officer
SellThu Apr 02
Hackman Jeffrey S.director, officer: Chief Executive Officer
SellThu Apr 02
Hackman Jeffrey S.director, officer: Chief Executive Officer
SellThu Apr 02
Company Info
Sector
Healthcare
Industry
—
Country
US
Exchange
NASDAQ
Beta
0.93
Fennec Pharmaceuticals Inc. operates as a biopharmaceutical company. Its product candidate in the clinical stage of development is PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina.